Globeflex Capital’s Co-Diagnostics CODX Stock Holding History

Globeflex Capital’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,349	Closed	-$1.24M	–	496
2022 Q2	$1.24M	Buy	+7,349	New	+$1.12M	0.3%	92

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Globeflex Capital's CODX Position: Q3 2022 in Review

Globeflex Capital sold out of Co-Diagnostics (CODX) in Q3 2022, closing a stake of 7,349 shares — an estimated $1.24M sold.

Globeflex Capital first reported a position in CODX in Q2 2022 and held it in 1 quarter. The position peaked at $1.24M in Q2 2022. 65 funds tracked by Wall St. Rank hold CODX as of Q3 2022.

Globeflex Capital reported no remaining Co-Diagnostics position as of Q3 2022 after selling out during the quarter.
Globeflex Capital sold 7,349 Co-Diagnostics shares in Q3 2022, an estimated $1.24M.
Globeflex Capital first reported a position in Co-Diagnostics in Q2 2022 and held it in 1 quarter.
Globeflex Capital's Co-Diagnostics position peaked at $1.24M in Q2 2022.
65 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2022.

Based on Globeflex Capital's 13F filing for Q3 2022, filed 14 Nov 2022.